治疗成人复发或难治性多发性骨髓瘤新药:免疫偶联物belantamab mafodotin  

New drug for the treatment of adult relapsed or refractory multiple myeloma:immunoconjugate belantamab mafodotin

作　　者：狄潘潘 DI Panpan(Pharmacy Intravenous Admixture Services,Bozhou People’s Hospital,Bozhou,236800,Anhui,China)

机构地区：[1]亳州市人民医院静配中心,安徽亳州236800

出　　处：《肿瘤药学》2022年第6期709-713,共5页Anti-Tumor Pharmacy

摘　　要：belantamab mafodotin((BLENREP))是由GlaxoSmithKline公司研发的靶向抗肿瘤药物,可选择性作用于恶性浆细胞表面的B细胞成熟抗原。该药于2020年8月5日获美国食品药品监督管理局(FDA)批准上市,用于治疗成人复发或难治性多发性骨髓瘤。临床试验表明,belantamab mafodotin具有较好的临床疗效,常见不良反应包括角膜病变、血小板减少症及贫血。本文主要对belantamab mafodotin的作用机制、用法用量、药动学、临床研究及不良反应等方面进行介绍,以期为临床用药提供一定的参考。Belantamab mafodotin(BLENREP)is a targeted anti-tumor drug developed by GlaxoSmithKline.It can selectively act on B cell maturation antigens on the surface of malignant plasma cells.The drug was approved by the U.S.Food and Drug Administration(FDA)on August 5,2020 for the treatment of relapsed or refractory multiple myeloma in adults.Clinical trials have shown that belantamab mafodotin has good clinical effects.Its common adverse reactions include corneal disease,thrombocytopenia and anemia.In this paper,we mainly introduced the mechanism of action,dosage,pharmacokinetics,clinical research and adverse reactions of belantamab mafodotin,in order to provide some reference for clinical medication.

关 键 词：belantamab mafodotin 免疫偶联药物 作用机制 临床研究 

分 类 号：R733.3[医药卫生—肿瘤] R730.51[医药卫生—临床医学]